An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events
- Resource Type
- Authors
- Mike Leach; Andrew Fyfe; R Campbell Tait; Katrina Farrell; Jonathan Allan
- Source
- Leukemia & Lymphoma. 57:2568-2574
- Subject
- Adult
Male
Cancer Research
Asparaginase
medicine.medical_specialty
Adolescent
Antineoplastic Agents
Context (language use)
030204 cardiovascular system & hematology
Antithrombins
Young Adult
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Aged
Retrospective Studies
business.industry
Incidence (epidemiology)
Antithrombin
Thrombosis
Retrospective cohort study
Hematology
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
medicine.disease
Surgery
Treatment Outcome
Oncology
chemistry
030220 oncology & carcinogenesis
Cohort
Drug Therapy, Combination
Female
Complication
business
medicine.drug
- Language
- ISSN
- 1029-2403
1042-8194
Thrombosis is a well-recognized complication of asparaginase therapy for acute lymphoblastic leukemia (ALL), associated with the depletion of antithrombin (AT). Following a high incidence of thrombotic episodes during induction therapy for ALL in our tertiary referral center, we prospectively instituted a protocol of AT replacement. Forty-five consecutive adolescents and adults with ALL treated with asparaginase-containing phase I induction protocols were included in this observational study. Fifteen received standard therapy with no replacement; the subsequent 30 were managed with the protocol described. One or more low AT levels (